CRISPR Therapeutics (CRSP) Q3 2026 earnings summary

Executive summary

• Q3 2026 revenue was $12.7m and net loss was $111.4m; cash, cash equivalents and marketable securities totaled $2,276.6m at September 30.

• CASGEVY generated $99m in Q3 revenue, up 30% quarter over quarter; more than 750 patients have initiated treatment worldwide.

• Liquidity is expected to fund operating expenses and capital expenditures for at least 24 months, excluding potential collaboration receipts and future financing.

• Pipeline progress included CTX310 RMAT designations, completed CTX611 Phase 2 enrollment and ongoing zugo-cel trials across autoimmune and cancer indications.

Financial highlights

• Q3 consolidated revenue was $12.7m vs. $0.9m a year earlier; $12.3m reflected deferred collaboration revenue recognized after Vertex declined an option.

• Q3 operating loss was $130.0m vs. $132.1m; net loss was $111.4m vs. $106.4m, including $11.7m of acquired in-process R&D expense for a Sirius milestone.

• Q3 R&D expense was $71.9m vs. $58.9m, G&A was $17.9m vs. $16.9m, and collaboration expense, net, was $41.3m vs. $57.1m.

• 9M revenue was $24.3m vs. $2.6m; operating loss was $377.6m vs. $509.8m and net loss was $325.5m vs. $451.0m.

• 9M R&D expense rose to $207.6m from $201.3m, while collaboration expense fell to $127.5m from $159.8m, primarily as the share of CASGEVY revenue increased.

Outlook and guidance

• Existing cash, cash equivalents and marketable securities are expected to fund operating expenses and capital expenditures for at least 24 months; estimate excludes additional financing and collaboration proceeds.

• R&D and G&A costs may increase as programs advance, trials expand, candidates are added and commercialization preparations proceed.

• CTX310 Phase 1b data and zugo-cel systemic sclerosis Phase 1 data were scheduled for November 2026 conferences; CTX611 and zugo-cel B-cell malignancy updates were anticipated in H2 2026.

• An update on options to nominate up to two additional siRNA targets was expected in 2027.